This site is intended for Healthcare Professionals only.

Alert: UK Faces Shortage Of Arthritis Drug Erelzi 50mg Pre-Filled Pen

Date:

Share post:

All affected healthcare providers have been cautioned against initiating any new patient on Erelzi products until supply issues are resolved

Hospitals and healthcare providers across the UK have been notified about the shortage of an anti-inflammatory medicine caused by a manufacturing failure.

The Department of Health and Social Care (DHSC) on Friday (3 May) issued a National Patient Safety Alert stating that Erelzi 50mg solution for injection in pre-filled pen will be out of stock from early May until mid-July 2024.

“The supply issues have been caused by a manufacturing failure resulting in delays in production and the implementation of global allocations,” it said.

However, it noted that homecare providers (Alcura, Healthnet and Sciensus) have sufficient stock to supply existing patients until mid/late May 2024.

Although Erelzi 50mg pre-filled syringes (PFS) are still available, they cannot support a full increase in demand, the DHSC warned.

Homecare providers are encouraged to assist patients in transitioning from Erelzi 50mg pre-filled pens to Erelzi 50mg pre-filled syringes during the shortage period, with a plan to revert to the original product once the shortage is resolved.

All healthcare providers involved in prescribing, dispensing, and administering Erelzi are also informed that Benepali (etanercept) 50mg and Enbrel (etanercept) 50mg pre-filled pen injections are still accessible and can adequately meet any sustained increase in demand.

However, all affected healthcare providers have been cautioned against initiating any new patient on Erelzi (etanercept) products until supply issues are resolved.

Erelzi contains the active substance etanercept and is one of three licensed biosimilars to Enbrel. It is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis. These products are available as a pre-filled pen or a pre-filled syringe.

The DHSC cautioned that Erelzi 50mg pre-filled syringes may not be suitable for patients with arthritis or problems with manual dexterity.

 

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...